<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CTJ</journal-id>
<journal-id journal-id-type="hwp">spctj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Trials</journal-id>
<journal-title>Clinical Trials</journal-title>
<issn pub-type="ppub">1740-7745</issn>
<issn pub-type="epub">1740-7753</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1740774511411593</article-id>
<article-id pub-id-type="publisher-id">10.1177_1740774511411593</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zohar</surname><given-names>Sarah</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Resche-Rigon</surname><given-names>Matthieu</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Chevret</surname><given-names>Sylvie</given-names></name>
</contrib>
<aff id="aff1-1740774511411593">Inserm, U717, Département de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, Paris 7 University, France</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1740774511411593">Sarah Zohar, Inserm, U 717, Département de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, AP-HP, Paris 7 University, Avenue Claude Vellefaux, 75475 Paris cedex 10, France Email: <email>sarah.zohar@univ-paris-diderot.fr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>10</volume>
<issue>3</issue>
<fpage>414</fpage>
<lpage>421</lpage>
<permissions>
<copyright-statement>© The Author(s), 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">The Society for Clinical Trials</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1740774511411593">
<title>Background</title>
<p>The Continual Reassessment Method typically is presented as the method of choice for the purpose of dose-finding based on a toxicity scale in phase I clinical trials. However, this adaptive statistical approach also can be applied easily to dose-finding experiments in phase II trials.</p>
</sec>
<sec id="section2-1740774511411593">
<title>Purpose</title>
<p>To provide a case study from a real clinical trial to illustrate the use of the Continual Reassessment Method in the context of phase II dose finding.</p>
</sec>
<sec id="section3-1740774511411593">
<title>Methods</title>
<p>The Continual Reassessment Method was used to model the dose-failure relationship in order to estimate the minimal effective dose. This approach was retrospectively used to determine the minimal effective dose of granulocyte colony-stimulating factor for peripheral blood stem cell collection in allografted patients following chemotherapy.</p>
</sec>
<sec id="section4-1740774511411593">
<title>Results</title>
<p>After the inclusion of 25 patients, the minimal effective dose was estimated to be the third dose level tested in the study.</p>
</sec>
<sec id="section5-1740774511411593">
<title>Limitations</title>
<p>The main limitation of the Continual Reassessment Method, which is not specific to the method but to the dose-finding setting, is that the empirical choice of the dose range can be either under or over-estimated. The method requires a calibration study prior to trial onset.</p>
</sec>
<sec id="section6-1740774511411593">
<title>Conclusions</title>
<p>Assuming that a dose-effect relationship is monotonically increasing, the use of the Continual Reassessment Method in phase II dose-finding studies allows the estimation of the minimum effective dose for further studies. Modeling the dose-failure relationship allows the direct use of available software developed for the Continual Reassessment Method in the context of phase I clinical trials.</p>
</sec>
</abstract>
</article-meta>
</front>
<body>
<sec id="section7-1740774511411593" sec-type="intro">
<title>Introduction</title>
<p>The assessment of dose response is an integral component of drug development, whether response is defined in terms of efficacy or toxicity. Phase I cancer dose-finding studies focus on finding the highest doses with acceptable toxicity, and are subject to the ethical constraint of minimizing the number of subjects treated at unacceptably toxic dose levels. Standard designs are algorithmic dose-escalation schemes, in which the dose of a new cytotoxic drug is gradually increased, starting with a dose level that is not expected to cause any significant toxicity and increasing until some doselimiting toxicity (DLT) is observed. The maximum tolerated dose (MTD) is usually defined as the highest dose level at which six patients have been treated with at most one patient experiencing the DLT, or the lower dose level whenever two or more patients experienced DLT at a higher dose level. In 1990, an alternative approach to estimating the MTD, the Continual Reassessment Method (CRM), was proposed by O’Quigley <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr1-1740774511411593">1</xref>]. This model-based approach aimed at finding a single quantile of the dose-toxicity curve and defined the MTD as the dose with the probability of DLT closest to a targeted probability, usually 25 or 30 percent. The CRM is an adaptive design, using all of the data available prior to the trial and all of the data accumulated during the trial to select the dose administered to each new patient.</p>
<p>However, the paradigm of dose selection based on toxicity does not apply for non-life-threatening diseases. In these settings, the specific objective of dose-finding trials is to identify the minimum dose that exhibits adequate drug activity, the minimum effective dose (MED) [<xref ref-type="bibr" rid="bibr2-1740774511411593">2</xref>]. The MED, ‘the smallest dose with a discernible useful effect’ [<xref ref-type="bibr" rid="bibr3-1740774511411593">3</xref>], defines the targeted dose of Phase II trials and could be considered as a dose to which some pre-specified proportion of a sample population responds. As a model for choosing a dose level at which a given percentage of patients experience an event, the CRM has been applied to dose-finding for phase II trials to select, from among a set of dose levels, the MED of the new drug [<xref ref-type="bibr" rid="bibr4-1740774511411593">4</xref><xref ref-type="bibr" rid="bibr5-1740774511411593"/>
<xref ref-type="bibr" rid="bibr6-1740774511411593"/>
<xref ref-type="bibr" rid="bibr7-1740774511411593"/>–<xref ref-type="bibr" rid="bibr8-1740774511411593">8</xref>]. This has also been applied to targeted cancer therapies, where efficacy does not increase monotonically with dose, making the MTD not optimal as a dose criterion [<xref ref-type="bibr" rid="bibr9-1740774511411593">9</xref>,<xref ref-type="bibr" rid="bibr10-1740774511411593">10</xref>].</p>
<p>To ensure consistency between the phase I and phase II settings in non-life-threatening disease, and potentially in cancer dose-finding trials of targeted therapies, efficacy failure appears to be a better outcome measure than success for two main reasons. First, the CRM is directed towards estimating the dose associated with a given quantile when the dose is escalated. Thus, to implement the same model in phase II, one can replace toxicity by efficacy failure and directly apply the available CRM software. Second, Phase II dose-finding trials aim to minimize failures while phase I dose finding aims to minimize toxicities. We compare in <xref ref-type="table" rid="table1-1740774511411593">Table 1</xref> the use of the CRM in a phase II dose-finding trial with its use in phase I cancer trials by highlighting both common and different features in the two settings.</p>
<table-wrap id="table1-1740774511411593" position="float">
<label>Table 1.</label>
<caption>
<p>Main comparison of phase I and phase II dose-finding trials when using the CRM</p>
</caption>
<graphic alternate-form-of="table1-1740774511411593" xlink:href="10.1177_1740774511411593-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Criteria</th>
<th align="left">Common features</th>
<th align="center" colspan="2">Specific features<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th align="left">Phase I dose-finding</th>
<th align="left">Phase II dose-finding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective</td>
<td>To find a quantile of the dose-effect curve</td>
<td>To find the MTD (maximum tolerated dose)</td>
<td>To find the MED (minimum effective dose)</td>
</tr>
<tr>
<td>Ethics constraints</td>
<td>Minimizing sample size</td>
<td>Minimizing those treated  at toxic doses</td>
<td>Minimizing those treated at ineffective doses</td>
</tr>
<tr>
<td>Outcome</td>
<td>Binary outcome</td>
<td>Dose-limiting toxicity (DLT/no-DLTs)</td>
<td>Treatment Response (Success/Failure)</td>
</tr>
<tr>
<td>Model</td>
<td>Pr(response|dose)</td>
<td>Pr(DLT|dose)</td>
<td>Pr(failure|dose)</td>
</tr>
<tr>
<td>Dose ordering</td>
<td>
<italic>k</italic> levels</td>
<td>
<italic>d<sub>1</sub></italic> &lt; <italic>d<sub>2</sub></italic> &lt; … &lt; <italic>d<sub>k</sub></italic></td>
<td>
<italic>d<sub>1</sub></italic> &gt; <italic>d<sub>2</sub></italic> &gt; … &gt; <italic>d<sub>k</sub></italic></td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Dose-finding trials should be distinguished from ‘dose-ranging’ phase II trials, where patients are randomized among dose groups that cover the dose range [<xref ref-type="bibr" rid="bibr11-1740774511411593">11</xref>]. In those trials, no attempt is made to target the MED sequentially; rather dose estimation is performed at the end of the trial. As a result, one or several groups of randomized patients are treated at ineffective or less effective dose levels. In contrast, the CRM attempts to allocate the maximum number of patients to the estimated MED.</p>
<p>The CRM has been applied to the design and analysis of several phase II clinical trials in which physicians did not want to over-treat patients, even when safety was not the major endpoint. This design has been used in trials conducted among neonates and infants [<xref ref-type="bibr" rid="bibr5-1740774511411593">5</xref>,<xref ref-type="bibr" rid="bibr6-1740774511411593">6</xref>,<xref ref-type="bibr" rid="bibr8-1740774511411593">8</xref>], of stem cell mobilization [<xref ref-type="bibr" rid="bibr7-1740774511411593">7</xref>], of pain treatment [<xref ref-type="bibr" rid="bibr12-1740774511411593">12</xref>], and among pregnant women [<xref ref-type="bibr" rid="bibr4-1740774511411593">4</xref>]. Recently, Beloeil <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr12-1740774511411593">12</xref>] conducted a phase II dose-finding clinical trial among patients suffering from moderate pain in the postoperative period in which they used the CRM. Unlike in previous clinical trials, the authors modeled the dose-success relationship suggesting a lack of well-accepted standards when using the CRM in the setting of phase II trials. The aim of this article is not to review the operational aspects of the CRM, which have received extensive attention [<xref ref-type="bibr" rid="bibr13-1740774511411593">13</xref><xref ref-type="bibr" rid="bibr14-1740774511411593"/>
<xref ref-type="bibr" rid="bibr15-1740774511411593"/>
<xref ref-type="bibr" rid="bibr16-1740774511411593"/>
<xref ref-type="bibr" rid="bibr17-1740774511411593"/>
<xref ref-type="bibr" rid="bibr18-1740774511411593"/>
<xref ref-type="bibr" rid="bibr19-1740774511411593"/>–<xref ref-type="bibr" rid="bibr20-1740774511411593">20</xref>], but to provide a case study from an actual clinical trial to illustrate in detail the use of the CRM in the context of phase II dose-finding.</p>
<sec id="section8-1740774511411593">
<title>Methods</title>
<p>The CRM uses a one-parameter mathematical model to express the probability of response (either toxicity or failure) as a monotonically increasing function of the dose. Let <italic>D</italic> be the set of <italic>k</italic> available doses, <italic>D = </italic>{<italic>d</italic><sub>1</sub>, <italic>d</italic><sub>2</sub>, … , <italic>d<sub>k</sub></italic>}. Let <inline-formula id="inline-formula1-1740774511411593">
<mml:math display="inline" id="math1-1740774511411593">
<mml:mrow>
<mml:mi>ψ</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mi>Pr</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>Y</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">|</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> (<inline-formula id="inline-formula2-1740774511411593">
<mml:math display="inline" id="math2-1740774511411593">
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo><mml:mo>…</mml:mo>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:math></inline-formula>) denote the parametric model for the probability of failure at dose <italic>d<sub>i</sub></italic>, where <italic>θ</italic> is the model parameter. Indeed, to identify a single chosen quantile, single-parameter models are often used [<xref ref-type="bibr" rid="bibr1-1740774511411593">1</xref>,<xref ref-type="bibr" rid="bibr21-1740774511411593">21</xref>]. The simplest and most widely used model is the power model:</p>
<p>
<disp-formula id="disp-formula1-1740774511411593">
<label>(1)</label>
<mml:math display="block" id="math3-1740774511411593">
<mml:mrow>
<mml:mi>ψ</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msubsup>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>θ</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-1740774511411593" xlink:href="10.1177_1740774511411593-eq1.tif"/>
</disp-formula>
</p>
<p>where the values of <italic>α<sub>i</sub></italic> are monotonically increasing pre-specified probabilities. The set of <italic>α<sub>i</sub></italic>, which is often referred to as the ‘working model,’ is defined by the initial guesses of the failure probabilities given by the clinicians; it does not require any specific mathematical shape except that the guesses should increase with the dose rank <italic>i</italic>. Alternatively, the single-parameter logistic model is also used:</p>
<p>
<disp-formula id="disp-formula2-1740774511411593">
<label>(2)</label>
<mml:math display="block" id="math4-1740774511411593">
<mml:mrow>
<mml:mi>ψ</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mi>exp</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:mi>θ</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:mi>θ</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mfrac>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-1740774511411593" xlink:href="10.1177_1740774511411593-eq2.tif"/>
</disp-formula>
</p>
<p>where the intercept, <italic>a</italic><sub>0</sub>, is fixed and <inline-formula id="inline-formula3-1740774511411593">
<mml:math display="inline" id="math5-1740774511411593">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>ψ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>, that is, the doses initially are expressed to fit the working model.</p>
<p>The CRM algorithm allocates the dose level closest to the currently estimated MED after each cohort of patients. For the purpose of estimation, the original CRM used a Bayesian algorithm, that is, one in which the parameter <italic>θ</italic> to be estimated from the trial data is considered as random. To quantify initial uncertainty regarding its value, a prior distribution is chosen before the trial onset, usually from the exponential family [<xref ref-type="bibr" rid="bibr13-1740774511411593">13</xref>,<xref ref-type="bibr" rid="bibr17-1740774511411593">17</xref>,<xref ref-type="bibr" rid="bibr18-1740774511411593">18</xref>,<xref ref-type="bibr" rid="bibr22-1740774511411593">22</xref><xref ref-type="bibr" rid="bibr23-1740774511411593"/>–<xref ref-type="bibr" rid="bibr24-1740774511411593">24</xref>]. Note that if the prior mean for <italic>θ</italic> is 1, then <italic>α<sub>d</sub></italic> is the prior mean of the failure probability at dose <italic>d</italic>. A likelihood version of the CRM (LCRM), which requires only the initial value of <italic>θ</italic> to be determined, has been proposed by O’Quigley and Shen [<xref ref-type="bibr" rid="bibr21-1740774511411593">21</xref>] for the estimation of the MED.</p>
<p>Prior to trial onset, some ‘model calibration’ is required. One calibration method consists of studying through simulations how the model choices (i.e., of the prior on <italic>θ</italic> and <italic>a</italic><sub>0</sub> in case of logistic modeling) potentially affect further estimates and the choice of the best values in terms of bias and percentage of correct dose selection (PCS) [<xref ref-type="bibr" rid="bibr22-1740774511411593">22</xref>,<xref ref-type="bibr" rid="bibr25-1740774511411593">25</xref>]. Methods other than simulation also can be used. Cheung and Chappell [<xref ref-type="bibr" rid="bibr26-1740774511411593">26</xref>] have developed a numerical technique to evaluate the CRM model sensitivity in order to choose one working model that will be used in the clinical trial. Lee and Cheung [<xref ref-type="bibr" rid="bibr27-1740774511411593">27</xref>] used indifference intervals with the working model selected by specifying a range of acceptable toxicity probabilities in addition to the target probability. Finally, Yin and Yuan [<xref ref-type="bibr" rid="bibr28-1740774511411593">28</xref>] proposed a Bayesian model averaging (BMA) approach to obtain the posterior estimates for the true toxicity probabilities by weighting the estimates from several working models.</p>
<p>The estimated response probability of the <italic>i</italic>th dose level after <italic>j</italic> patients have been treated is given by <inline-formula id="inline-formula4-1740774511411593">
<mml:math display="inline" id="math6-1740774511411593">
<mml:mrow>
<mml:mi>ψ</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>θ</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mspace width="0.25em"/>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>, where <inline-formula id="inline-formula5-1740774511411593">
<mml:math display="inline" id="math7-1740774511411593">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mover>
<mml:mrow>
<mml:mi>θ</mml:mi>
</mml:mrow>
<mml:mo>^</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> is the estimated value of the model parameter after <italic>j</italic> included patients. Thus, the dose level assigned to the next cohort of patients is the dose level with the estimated failure probability closest to the failure target but without skipping doses. The estimated MED at the end of the trial is the dose level with the failure probability closest to the target probability. A confidence or credibility interval of the failure probability associated with the MED is then computed.</p>
<p>The CRM is not difficult to program (see [<xref ref-type="bibr" rid="bibr29-1740774511411593">29</xref>]). Nevertheless, specific software systems have been proposed for implementing the CRM in phase I cancer trials. Modeling the dose-failure relationship allows the direct use of these software packages, such as, (i) dfcrm, an R package developed by Ken Cheung, Department of Biostatistics, Mailman School ofPublic Health, Columbia University (<ext-link ext-link-type="uri" xlink:href="http://cran.r-project.org/web/packages/dfcrm/index.html">http://cran.r-project.org/web/packages/dfcrm/index.html</ext-link>); (ii) CRM, a software package developed by the M.D. Anderson Cancer Center, Houston (<ext-link ext-link-type="uri" xlink:href="http://biostatistics.mdanderson.org/SoftwareDownload/">http://biostatistics.mdanderson.org/SoftwareDownload/</ext-link>); and (iii) BPCT, a software package developed by the Inserm Biostatistics team of Saint-Louis hospital, France.</p>
</sec>
</sec>
<sec id="section9-1740774511411593">
<title>MED estimation using the CRM: a case study</title>
<p>A phase II dose-finding trial using a Bayesian CRM design was designed and conducted with close collaboration between clinicians, pharmacologists, and statisticians. The goal was to find the minimal effective dose of granulocyte colony-stimulating factor (G-CSF) for peripheral blood stem cell (PBSC) collection in allograft patients following chemotherapy [<xref ref-type="bibr" rid="bibr7-1740774511411593">7</xref>]. The success of PBSC mobilization was defined by harvesting 3 × 10<sup>6</sup> CD34 cells/kg or more; otherwise, the patient outcome was considered a failure. The aim was to find, among these five dose levels, the dose most closely associated with a mobilization failure of 10%. This lower bound for the therapeutically useful dose level was derived from previous studies [<xref ref-type="bibr" rid="bibr30-1740774511411593">30</xref>,<xref ref-type="bibr" rid="bibr31-1740774511411593">31</xref>].</p>
</sec>
<sec id="section10-1740774511411593">
<title>Dose-failure modeling</title>
<p>The MED was set as the dose of G-CSF associated with the probability of failure closest to 0.10. We ordered five doses in decreasing order as follows: <italic>d</italic><sub>1</sub> = 150, <italic>d</italic><sub>2</sub> = 125, <italic>d</italic><sub>3</sub> = 100, <italic>d</italic><sub>4</sub> = 75, and <italic>d</italic><sub>5</sub> = 50 (expressed in µg/m<sup>2</sup>). Each of the dose levels was associated with an initial guess of the failure probability through an implicit idea of the dose-response relationship based on findings from the literature; the working model for the probabilities of failure was fixed at (0.1, 0.15, 0.2, 0.25, 0.3) [<xref ref-type="bibr" rid="bibr31-1740774511411593">31</xref>].</p>
</sec>
<sec id="section11-1740774511411593">
<title>Model calibration using simulations</title>
<p>Before the beginning of the trial, we calibrated the model parameters, that is, the logistic model intercept <italic>a</italic><sub>0</sub> and the prior distribution of the model parameter <italic>θ</italic>, by evaluating the performances of the CRM under each of six dose-failure curves that were considered to encompass the range of plausible dose-failure curves (<xref ref-type="fig" rid="fig1-1740774511411593">Figure 1</xref>). For each curve, we simulated 1000 independent replications of the same trial based on 25 enrolled patients, with response data randomly drawn from the actual dose-failure curve. The CRM was applied to define the dose level to be administered to the next patient; the procedure was repeated until the sample size had been reached. From these 1000 replicated trials, we computed the PCS and the bias, which was estimated by the mean difference between the mean posterior estimated failure probability of the selected dose level at the end of the trial and the underlying true failure rate of that dose level (<xref ref-type="table" rid="table2-1740774511411593">Table 2</xref>).</p>
<fig id="fig1-1740774511411593" position="float">
<label>Figure 1.</label>
<caption>
<p>Dose-failure scenarios used in the operating characteristics study.</p>
</caption>
<graphic xlink:href="10.1177_1740774511411593-fig1.tif"/>
</fig>
<table-wrap id="table2-1740774511411593" position="float">
<label>Table 2.</label>
<caption>
<p>Percentage of correct selection (PCS) and bias for each value of <italic>a</italic><sub>0</sub>, and the mean of the exponential prior distribution</p>
</caption>
<graphic alternate-form-of="table2-1740774511411593" xlink:href="10.1177_1740774511411593-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="left" colspan="6">Scenarios<hr/></th>
</tr>
<tr>
<th align="left">
<italic>a</italic>
<sub>0</sub>
</th>
<th align="left">Exponential prior mean</th>
<th align="left">1</th>
<th align="left">2</th>
<th align="left">3</th>
<th align="left">4</th>
<th align="left">5</th>
<th align="left">6</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="8">PCS (%)</td>
</tr>
<tr>
<td>1.00</td>
<td>2.00</td>
<td>
<bold>72</bold>
</td>
<td>28</td>
<td>58</td>
<td>
<bold>98</bold>
</td>
<td>58</td>
<td>42</td>
</tr>
<tr>
<td>1.00</td>
<td>1.00</td>
<td>69</td>
<td>27</td>
<td>56</td>
<td>
<bold>99</bold>
</td>
<td>56</td>
<td>56</td>
</tr>
<tr>
<td>1.00</td>
<td>0.50</td>
<td>57</td>
<td>29</td>
<td>
<bold>60</bold>
</td>
<td>
<bold>98</bold>
</td>
<td>
<bold>60</bold>
</td>
<td>64</td>
</tr>
<tr>
<td>2.00</td>
<td>2.00</td>
<td>
<bold>70</bold>
</td>
<td>23</td>
<td>59</td>
<td>
<bold>99</bold>
</td>
<td>59</td>
<td>55</td>
</tr>
<tr>
<td>2.00</td>
<td>1.00</td>
<td>58</td>
<td>20</td>
<td>49</td>
<td>96</td>
<td>49</td>
<td>
<bold>66</bold>
</td>
</tr>
<tr>
<td>2.00</td>
<td>0.50</td>
<td>58</td>
<td>28</td>
<td>54</td>
<td>95</td>
<td>54</td>
<td>
<bold>68</bold>
</td>
</tr>
<tr>
<td>3.00</td>
<td>2.00</td>
<td>60</td>
<td>33</td>
<td>52</td>
<td>
<bold>99</bold>
</td>
<td>52</td>
<td>57</td>
</tr>
<tr>
<td>3.00</td>
<td>1.00</td>
<td>64</td>
<td>
<bold>37</bold>
</td>
<td>41</td>
<td>
<bold>98</bold>
</td>
<td>41</td>
<td>
<bold>66</bold>
</td>
</tr>
<tr>
<td>3.00</td>
<td>0.50</td>
<td>59</td>
<td>28</td>
<td>59</td>
<td>
<bold>99</bold>
</td>
<td>59</td>
<td>65</td>
</tr>
<tr>
<td>4.00</td>
<td>2.00</td>
<td>
<bold>70</bold>
</td>
<td>26</td>
<td>43</td>
<td>
<bold>98</bold>
</td>
<td>43</td>
<td>58</td>
</tr>
<tr>
<td>4.00</td>
<td>1.00</td>
<td>57</td>
<td>22</td>
<td>45</td>
<td>
<bold>98</bold>
</td>
<td>45</td>
<td>63</td>
</tr>
<tr>
<td>4.00</td>
<td>0.50</td>
<td>59</td>
<td>26</td>
<td>48</td>
<td>97</td>
<td>48</td>
<td>60</td>
</tr>
<tr>
<td colspan="8">
<bold>Bias</bold>
</td>
</tr>
<tr>
<td>1.00</td>
<td>2.00</td>
<td>0.016</td>
<td>
<bold>0.000</bold>
</td>
<td>0.009</td>
<td>0.029</td>
<td>0.009</td>
<td>0.016</td>
</tr>
<tr>
<td>1.00</td>
<td>1.00</td>
<td>−<bold>0.001</bold></td>
<td>−<bold>0.003</bold></td>
<td>−<bold>0.003</bold></td>
<td>0.014</td>
<td>−<bold>0.003</bold></td>
<td>0.004</td>
</tr>
<tr>
<td>1.00</td>
<td>0.50</td>
<td>−0.016</td>
<td>−0.017</td>
<td>−0.023</td>
<td>0.011</td>
<td>−0.023</td>
<td>−0.015</td>
</tr>
<tr>
<td>2.00</td>
<td>2.00</td>
<td>0.008</td>
<td>−<bold>0.001</bold></td>
<td>−0.006</td>
<td>0.030</td>
<td>−0.006</td>
<td>0.004</td>
</tr>
<tr>
<td>2.00</td>
<td>1.00</td>
<td>−0.016</td>
<td>−0.023</td>
<td>−0.012</td>
<td>0.008</td>
<td>−0.012</td>
<td>−0.009</td>
</tr>
<tr>
<td>2.00</td>
<td>0.50</td>
<td>−0.020</td>
<td>−0.017</td>
<td>−0.004</td>
<td>−0.011</td>
<td>−0.004</td>
<td>−0.013</td>
</tr>
<tr>
<td>3.00</td>
<td>2.00</td>
<td>−0.006</td>
<td>−<bold>0.003</bold></td>
<td>−0.009</td>
<td>0.013</td>
<td>−0.009</td>
<td>−<bold>0.002</bold></td>
</tr>
<tr>
<td>3.00</td>
<td>1.00</td>
<td>−0.011</td>
<td>−0.019</td>
<td>−<bold>0.001</bold></td>
<td>
<bold>0.003</bold>
</td>
<td>−<bold>0.001</bold></td>
<td>−0.011</td>
</tr>
<tr>
<td>3.00</td>
<td>0.50</td>
<td>−0.013</td>
<td>−0.019</td>
<td>−0.013</td>
<td>0.004</td>
<td>−0.013</td>
<td>−0.013</td>
</tr>
<tr>
<td>4.00</td>
<td>2.00</td>
<td>0.004</td>
<td>−0.008</td>
<td>0.011</td>
<td>0.012</td>
<td>0.011</td>
<td>
<bold>0.001</bold>
</td>
</tr>
<tr>
<td>4.00</td>
<td>1.00</td>
<td>−0.017</td>
<td>−0.025</td>
<td>
<bold>0.002</bold>
</td>
<td>−<bold>0.003</bold></td>
<td>
<bold>0.002</bold>
</td>
<td>−0.010</td>
</tr>
<tr>
<td>4.00</td>
<td>0.50</td>
<td>−0.017</td>
<td>−0.015</td>
<td>0.005</td>
<td>−<bold>0.002</bold></td>
<td>0.005</td>
<td>−0.013</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1740774511411593">
<p>For each combination of parameters, the best performances for each scenario are presented in bold.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The choice of the values of <italic>a</italic><sub>0</sub> and the mean of the exponential prior were guided by pairs of values, insuring, in all scenarios, a high average PCS over all independent replications of the trial together with a low average bias. Based on the simulation findings, we chose <italic>a</italic><sub>0</sub> = 3 and a prior mean of <italic>θ</italic> equal to 2 which give high PCS as well as low bias (even if other combinations could be also chosen). The resulting dose-failure model, exhibiting the redefined dose scale, <inline-formula id="inline-formula6-1740774511411593">
<mml:math display="inline" id="math8-1740774511411593">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>x</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mtext>logit</mml:mtext>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>α</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>−</mml:mo>
<mml:mn>3</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">/</mml:mo>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:math></inline-formula>, from <italic>i = 1, … , 5</italic>. Rather than doing a simulation study in order to calibrate the CRM mode, we could have used the algorithm proposed by Lee and Cheung [<xref ref-type="bibr" rid="bibr27-1740774511411593">27</xref>] which is implemented in the ‘dfcrm’ R package. In this case, the investigators are not asked for initial guesses but for the desired half width of the indifference intervals and the prior guess of the MED level. The function ‘getprior’ will then generate a working model for the CRM.</p>
</sec>
<sec id="section12-1740774511411593">
<title>Trial conduct and analysis</title>
<p>The first patient received the dose level guessed to be the MED before the trial onset, namely the first dose level <italic>d</italic><sub>1</sub> = 150 µg/m<sup>2</sup>, and experienced a success (i.e., absence of failure). The posterior mean of the model parameters then was re-estimated. The next patient was administered the dose level with the posterior estimate of failure probability closest to 10%, still the highest dose level (d<sub>1</sub>) with associated failure probability estimate of 0.06. The second patient was also a success, so the dose recommended to the third patient was d<sub>2</sub>, due to the posterior estimate of the failure probability of 9% at that dose level. This process was repeated until the predetermined fixed sample size of 25 was reached (<xref ref-type="fig" rid="fig2-1740774511411593">Figure 2</xref>). At that point, the posterior estimated failure probabilities were 0.04, 0.06, 0.09, 0.12, and 0.16 associated with the doses 150, 125, 100, 75, and 50 (expressed in µg/m<sup>2</sup>), respectively. The dose level d<sub>3</sub>, 100 µg/m<sup>2</sup>, was found to be the MED, with a failure probability estimated at 9% (95% credibility interval: 1.7%–25.8%).</p>
<fig id="fig2-1740774511411593" position="float">
<label>Figure 2.</label>
<caption>
<p>Dose allocation of the G-CSF trial. The arrows and ‘F’ represent observed failures. Note that the 7<italic>th</italic> patient was included before the response of the 6<italic>th</italic> patient was known, so the 7<italic>th</italic> patient was included at the same dose level as the 6<italic>th</italic> patient.</p>
</caption>
<graphic xlink:href="10.1177_1740774511411593-fig2.tif"/>
</fig>
<p>To examine whether the use of a standard likelihood inference would have modified the estimated MED, we retrospectively applied the LCRM [<xref ref-type="bibr" rid="bibr21-1740774511411593">21</xref>] for the estimation of the MED, on the basis of the whole data set. The failure probabilities of the five dose levels were estimated to be 0.030, 0.055, 0.085, 0.120, and 0.160; that is, slightly below those found when using the Bayes inference. This did not affect the conclusion of the trial, in which the third dose level (100 µg/m<sup>2</sup>) was estimated to be the MED, with an estimated failure probability of 8.5%.</p>
<p>Finally, we examined the dose-success relationship rather than the dose-failure relationship, targeting 90% success, with a working model for <italic>d</italic><sub>1</sub> = 50, <italic>d</italic><sub>2</sub> = 75, <italic>d</italic><sub>3</sub> = 100, <italic>d</italic><sub>4</sub> = 125, and <italic>d</italic><sub>5</sub> = 150, of (0.7, 0.75, 0.8, 0.85, 0.9). It is worth noting that, in contrast to the previous findings, the resulting estimated success probabilities based on the observations recorded at the end of the trial would have been (0.882, 0.902, 0.912, 0.923, 0.935), corresponding to failure probabilities of 0.118, 0.098, 0.088, 0.077, and 0.065, respectively. Thus, the recommended MED would have been the second dose level <italic>d</italic><sub>2</sub> = 75 µg/m<sup>2</sup>, with an estimated failure probability of 9.8%. Note that the estimated dose-response relationship was almost flat over the entire dose range (<xref ref-type="fig" rid="fig3-1740774511411593">Figure 3</xref>). The estimated failure probability associated with the dose level of 100 µg/m<sup>2</sup> was 8.8%, close to the above estimates, using either Bayes CRM (9%) or LCRM (8.5%) to model the dose-failure relationship.</p>
<fig id="fig3-1740774511411593" position="float">
<label>Figure 3.</label>
<caption>
<p>Estimated dose-failure relationships using the Bayesian estimate (CRM), the maximum likelihood estimate (ML), and the Bayesian estimate when modeling the dose-success relationship.</p>
</caption>
<graphic xlink:href="10.1177_1740774511411593-fig3.tif"/>
</fig>
<p>With such a flat dose-response curve, one could weight the doses according to these probabilities and randomly select one for future use. To better demonstrate how this works, we plotted the logistic function, fixing the intercept (a<sub>0</sub>) at 3 and using three values of the slope parameter (θ; 0.6, 2, and 2.8 (<xref ref-type="fig" rid="fig4-1740774511411593">Figure 4</xref>)). These values correspond to the first quartile, mean, and the third quartile of the prior distribution of θ. <xref ref-type="fig" rid="fig4-1740774511411593">Figure 4</xref> shows that the area that could be explored, prior to the trial onset, appears to be larger under the dose-failure modeling than the dose-success with the same intercept usually used for the CRM [<xref ref-type="bibr" rid="bibr22-1740774511411593">22</xref>,<xref ref-type="bibr" rid="bibr27-1740774511411593">27</xref>]. Indeed, using the dose-failure relationship will let the estimation of the model parameter to be chosen from a wider area. For instance, under the dose-failure relationship the dose 150 µg/m<sup>2</sup> can be estimated in a failure probability range starting from 0.01 to 0.8. By contrast using the dose-success relationship, for the same dose level, the probability range is narrower starting from 0.48 to 0.9.</p>
<fig id="fig4-1740774511411593" position="float">
<label>Figure 4.</label>
<caption>
<p>The logistic distribution features prior to the trial onset. Logistic function with a fixed intercept (a<sub>0</sub>) equal to 3 and three slope values of θ equal to 0.6 (Q1), 2 (mean) and 2.8 (Q3 of the prior distribution, respectively). The failure and the success targets are represented by dashed lines (0.1 and 0.9 respectively). The gray stripes represent the redefined dose range under the dose-failure relationship (left) and under the dose-success relationship (right). The “hatched” area represents the potential values of (dose, probability) pairs that can be explored during the trial.</p>
</caption>
<graphic xlink:href="10.1177_1740774511411593-fig4.tif"/>
</fig>
<p>The differences in the estimates obtained by modeling either the dose-failure or the dose-success relationships could be explained by initial values of the model parameters (a<sub>0</sub> and prior mean of θ) that were unchanged in both settings. If <italic>a<sub>0</sub></italic> = −3 rather than 3 were used when modeling the dose-success relationship, the two models would have chosen the same MED, that is, <italic>d</italic><sub>3</sub> = 100 µg/m<sup>2</sup>. This emphasizes the need to perform a simulation study for calibrating the initial parameter values to model the dose-success curve. Once a proper calibration has been performed, the only difference between modeling dose-failure rather than the dose-success lies in the dose selection algorithm. Modeling the dose-success curve produces dose escalation, starting with doses that are likely to be ineffective. If the dose-failure curve is modeled, with dose de-escalation, patients will first be administered doses more likely to be effective</p>
<p>When targeting the 10th percentile of the dose-failure (or the 90th percentile of the dose-success) relationship, some convergence properties can fail. The design objective is to estimate extreme percentiles of a dose–response distribution as precisely as possible using the smallest number of experimental subjects possible. In situations in which prior opinion regarding the probability of failure ranges from 1% to 50%, the impact of an early unexpected outcome on the allocated doses can be high. In this case, it would be more appropriate to use the weighted CRM (wCRM) [<xref ref-type="bibr" rid="bibr32-1740774511411593">32</xref>], in which the influence of the early observations can be decreased.</p>
</sec>
<sec id="section13-1740774511411593" sec-type="conclusions">
<title>Conclusions</title>
<p>Using the CRM in phase II dose-finding studies can be used to find the MED, while treating more patients with higher doses that are still likely to be effective. Modeling the dose-failure relationship allows the direct use of available software developed for the CRM in the context of phase I clinical trials. By contrast, modeling the dose-success relationship requires model calibration before the trial onset. The CRM can allocate more patients to the MTD compared to a standard ‘3+3’ design. Moreover, it allows the estimation of the variability of the point estimate of efficacy, which is not easily done with algorithmic designs. It does not solve the problem of initial over- or underestimation of the dose range, but CRM versions have been proposed that allow extension of that range if further doses are needed [<xref ref-type="bibr" rid="bibr33-1740774511411593">33</xref>].</p>
</sec>
</body>
<back>
<ack>
<p>We thank the Editor in chief and reviewers for valuable input that greatly improved this article.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>Institut National du Cancer, grant number 2010-1-PL SHS-10.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1740774511411593">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Quigley</surname><given-names>J</given-names></name>
<name><surname>Pepe</surname><given-names>M</given-names></name>
<name><surname>Fisher</surname><given-names>L</given-names></name>
</person-group>. <article-title>Continual reassessment method: a practical design for phase 1 clinical trials in cancer</article-title>. <source>Biometrics</source> <year>1990</year>; <volume>46</volume>: <fpage>33</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr2-1740774511411593">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kummar</surname><given-names>S</given-names></name>
<name><surname>Gutierrez</surname><given-names>M</given-names></name>
<name><surname>Doroshow</surname><given-names>JH</given-names></name>
<name><surname>Murgo</surname><given-names>AJ</given-names></name>
</person-group>. <article-title>Drug development in oncology: classical cytotoxics and molecularly targeted agents</article-title>. <source>Br J Clin Pharmacol</source> <year>2006</year>; <volume>62</volume>: <fpage>15</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr3-1740774511411593">
<label>3.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Armitage</surname><given-names>P</given-names></name>
<name><surname>Colton</surname><given-names>T</given-names></name>
</person-group>. <source>Encyclopedia of Biostatistics</source>. <publisher-name>John Wiley and Sons</publisher-name>, <publisher-loc>New-York</publisher-loc>, <year>1998</year>.</citation>
</ref>
<ref id="bibr4-1740774511411593">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Spirlet</surname><given-names>M</given-names></name>
<name><surname>Treluyer</surname><given-names>JM</given-names></name>
<name><surname>Chevret</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Tocolytic effects of intravenous nitroglycerin</article-title>. <source>Fundam Clin Pharmacol</source> <year>2004</year>; <volume>18</volume>: <fpage>207</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr5-1740774511411593">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Desfrere</surname><given-names>L</given-names></name>
<name><surname>Zohar</surname><given-names>S</given-names></name>
<name><surname>Morville</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method</article-title>. <source>J Clin Pharm Ther</source> <year>2005</year>; <volume>30</volume>: <fpage>121</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr6-1740774511411593">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fabre</surname><given-names>E</given-names></name>
<name><surname>Chevret</surname><given-names>S</given-names></name>
<name><surname>Piechaud</surname><given-names>JF</given-names></name>
<etal/>
</person-group>. <article-title>An approach for dose finding of drugs in infants: sedation by midazolam studied using the continual reassessment method</article-title>. <source>Br J Clin Pharmacol</source> <year>1998</year>; <volume>46</volume>: <fpage>395</fpage>–<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr7-1740774511411593">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lefrere</surname><given-names>F</given-names></name>
<name><surname>Zohar</surname><given-names>S</given-names></name>
<name><surname>Bresson</surname><given-names>JL</given-names></name>
<etal/>
</person-group>. <article-title>A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin’s lymphoma</article-title>. <source>Haematologica</source> <year>2006</year>; <volume>91</volume>: <fpage>550</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr8-1740774511411593">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Treluyer</surname><given-names>JM</given-names></name>
<name><surname>Zohar</surname><given-names>S</given-names></name>
<name><surname>Rey</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Minimum effective dose of midazolam for sedation of mechanically ventilated neonates</article-title>. <source>J Clin Pharm Ther</source> <year>2005</year>; <volume>30</volume>: <fpage>479</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr9-1740774511411593">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Le Tourneau</surname><given-names>C</given-names></name>
<name><surname>Lee</surname><given-names>JJ</given-names></name>
<name><surname>Siu</surname><given-names>LL</given-names></name>
</person-group>. <article-title>Dose escalation methods in phase I cancer clinical trials</article-title>. <source>J Natl Cancer Inst</source> <year>2009</year>; <volume>101</volume>: <fpage>708</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr10-1740774511411593">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zohar</surname><given-names>S</given-names></name>
<name><surname>O’Quigley</surname><given-names>J</given-names></name>
</person-group>. <article-title>Re: Dose escalation methods in phase I cancer clinical trials</article-title>. <source>J Natl Cancer Inst</source> <year>2009</year>; <volume>101</volume>: <fpage>1732</fpage>–<lpage>33</lpage> author reply 1733–35.</citation>
</ref>
<ref id="bibr11-1740774511411593">
<label>11.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Ting</surname><given-names>N</given-names></name>
</person-group>. <article-title>General considerations in dose response study designs</article-title>. In <person-group person-group-type="editor">
<name><surname>Ting</surname><given-names>N</given-names></name>
</person-group>. (ed.). <source>Dose Finding in Drug Development</source>. <publisher-name>Springer</publisher-name>, <publisher-loc>Berlin</publisher-loc>, <year>2006</year>.</citation>
</ref>
<ref id="bibr12-1740774511411593">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beloeil</surname><given-names>H</given-names></name>
<name><surname>Eurin</surname><given-names>M</given-names></name>
<name><surname>Thevenin</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Effective dose of nefopam in 80% of patients (ED80): a study using the continual reassessment method</article-title>. <source>Br J Clin Pharmacol</source> <year>2007</year>; <volume>64</volume>: <fpage>686</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr13-1740774511411593">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahn</surname><given-names>C</given-names></name>
</person-group>. <article-title>An evaluation of phase I cancer clinical trial designs</article-title>. <source>Stat Med</source> <year>1998</year>; <volume>17</volume>: <fpage>1537</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr14-1740774511411593">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braun</surname><given-names>TM</given-names></name>
<name><surname>Levine</surname><given-names>JE</given-names></name>
<name><surname>Ferrara</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM</article-title>. <source>Control Clin Trials</source> <year>2003</year>; <volume>24</volume>: <fpage>669</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr15-1740774511411593">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Faries</surname><given-names>D</given-names></name>
</person-group>. <article-title>Practical modifications of the continual reassessment method for phase I cancer clinical trials</article-title>. <source>J Biopharm Stat</source> <year>1994</year>; <volume>4</volume>: <fpage>147</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr16-1740774511411593">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ishizuka</surname><given-names>N</given-names></name>
<name><surname>Ohashi</surname><given-names>Y</given-names></name>
</person-group>. <article-title>The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials</article-title>. <source>Stat Med</source> <year>2001</year>; <volume>20</volume>: <fpage>2661</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr17-1740774511411593">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Korn</surname><given-names>EL</given-names></name>
<name><surname>Midthune</surname><given-names>D</given-names></name>
<name><surname>Chen</surname><given-names>TT</given-names></name>
<etal/>
</person-group>. <article-title>A comparison of two phase I trial designs</article-title>. <source>Stat Med</source> <year>1994</year>; <volume>13</volume>: <fpage>1799</fpage>–<lpage>806</lpage>.</citation>
</ref>
<ref id="bibr18-1740774511411593">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moller</surname><given-names>S</given-names></name>
</person-group>. <article-title>An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses</article-title>. <source>Stat Med</source> <year>1995</year>; <volume>14</volume>: <fpage>911</fpage>–<lpage>22</lpage>; discussion 923.</citation>
</ref>
<ref id="bibr19-1740774511411593">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Quigley</surname><given-names>J</given-names></name>
</person-group>. <article-title>Curve-free and model-based continual reassessment method designs</article-title>. <source>Biometrics</source> <year>2002</year>; <volume>58</volume>: <fpage>245</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr20-1740774511411593">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yuan</surname><given-names>Z</given-names></name>
<name><surname>Chappell</surname><given-names>R</given-names></name>
<name><surname>Bailey</surname><given-names>H</given-names></name>
</person-group>. <article-title>The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach</article-title>. <source>Biometrics</source> <year>2007</year>; <volume>63</volume>: <fpage>173</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr21-1740774511411593">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Quigley</surname><given-names>J</given-names></name>
<name><surname>Shen</surname><given-names>LZ</given-names></name>
</person-group>. <article-title>Continual reassessment method: a likelihood approach</article-title>. <source>Biometrics</source> <year>1996</year>; <volume>52</volume>: <fpage>673</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr22-1740774511411593">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chevret</surname><given-names>S</given-names></name>
</person-group>. <article-title>The continual reassessment method in cancer phase I clinical trials: a simulation study</article-title>. <source>Stat Med</source> <year>1993</year>; <volume>12</volume>: <fpage>1093</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr23-1740774511411593">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goodman</surname><given-names>SN</given-names></name>
<name><surname>Zahurak</surname><given-names>ML</given-names></name>
<name><surname>Piantadosi</surname><given-names>S</given-names></name>
</person-group>. <article-title>Some practical improvements in the continual reassessment method for phase I studies</article-title>. <source>Stat Med</source>, <year>1995</year>; <volume>14</volume>: <fpage>1149</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr24-1740774511411593">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Quigley</surname><given-names>J</given-names></name>
<name><surname>Chevret</surname><given-names>S</given-names></name>
</person-group>. <article-title>Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study</article-title>. <source>Stat Med</source> <year>1991</year>; <volume>10</volume>: <fpage>1647</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr25-1740774511411593">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thall</surname><given-names>PF</given-names></name>
<name><surname>Russell</surname><given-names>KE</given-names></name>
</person-group>. <article-title>A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials</article-title>. <source>Biometrics</source> <year>1998</year>; <volume>54</volume>: <fpage>251</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr26-1740774511411593">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheung</surname><given-names>YK</given-names></name>
<name><surname>Chappell</surname><given-names>R</given-names></name>
</person-group>. <article-title>A simple technique to evaluate model sensitivity in the continual reassessment method</article-title>. <source>Biometrics</source> <year>2002</year>; <volume>58</volume>: <fpage>671</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr27-1740774511411593">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>SM</given-names></name>
<name><surname>Cheung</surname><given-names>YK</given-names></name>
</person-group>. <article-title>Model calibration in the continual reassessment method</article-title>. <source>Clin Trials</source> <year>2009</year>; <volume>6</volume>: <fpage>227</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr28-1740774511411593">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yin</surname><given-names>G</given-names></name>
<name><surname>Yuan</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Bayesian model averaging continual reassessment method in phase I clinical trials</article-title>. <source>J Am Stat Assoc</source> <year>2009</year>; <volume>104</volume>: <fpage>954</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr29-1740774511411593">
<label>29.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Chevret</surname><given-names>S</given-names></name>
</person-group>. <source>Statistical Methods for Dose-Finding Experiments</source>. <publisher-name>John Wiley and Sons</publisher-name>, <publisher-loc>Chichester</publisher-loc>, <year>2006</year>.</citation>
</ref>
<ref id="bibr30-1740774511411593">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haas</surname><given-names>R</given-names></name>
<name><surname>Mohle</surname><given-names>R</given-names></name>
<name><surname>Fruhauf</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma</article-title>. <source>Blood</source> <year>1994</year>; <volume>83</volume>: <fpage>3787</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr31-1740774511411593">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lefrere</surname><given-names>F</given-names></name>
<name><surname>Belanger</surname><given-names>C</given-names></name>
<name><surname>Audat</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>The dose of granulocyte-colony-stimulating factor after chemopriming treatment does not influence apheresis yield of progenitor cells: a retrospective study of 91 cases</article-title>. <source>Transfusion</source> <year>1999</year>; <volume>39</volume>: <fpage>1207</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr32-1740774511411593">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Resche-Rigon</surname><given-names>M</given-names></name>
<name><surname>Zohar</surname><given-names>S</given-names></name>
<name><surname>Chevret</surname><given-names>S</given-names></name>
</person-group>. <article-title>Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes</article-title>. <source>Clin Trials</source> <year>2008</year>; <volume>5</volume>: <fpage>595</fpage>–<lpage>606</lpage>.</citation>
</ref>
<ref id="bibr33-1740774511411593">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zohar</surname><given-names>S</given-names></name>
<name><surname>Chevret</surname><given-names>S</given-names></name>
</person-group>. <article-title>The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies</article-title>. <source>Stat Med</source> <year>2001</year>; <volume>20</volume>: <fpage>2827</fpage>–<lpage>43</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>